Two cases of bile duct carcinoma which showed remarkable response to a combination of S-1 plus cisplatinum (CDDP)

Journal of Applied Research

Volumn 5, Issue 3, 2005, Pages 487-491

  Hayashi, Kazuhiko ^a   Uchida, Kazumi ^a   Yamamoto, Masakazu ^a   Yoshitoshi, Kenji ^a   Takasaki, Ken ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Chemotherapy; Cholangiocarcinoma; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CISPLATIN;

ADULT; ANOREXIA; ARTICLE; BILE DUCT CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; ECHOGRAPHY; EPIGASTRIC PAIN; HUMAN; LIVER HILUS; LIVER NODULE; LYMPH NODE METASTASIS; MALE; NEEDLE BIOPSY; SURVIVAL TIME; THROMBOCYTOPENIA; TUMOR VOLUME;

EID: 26844477466     PISSN: 1537064X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Greenlee RT, Hill-Harmon MB, Murray T, et al. Cancer statistics 2001. CA Cancer J Clin. 2001;51:15-36.
2. De Groen PC, Gores GJ, La Russo NF, et al. Biliary tract cancers. N Engl J Med. 1999;341:1368-1378.
3. Henson DE, Albores-Saavedra J, Corle D. Carcinoma of the gallbladder. Histologic types, stage of disease, grade, and survival rates. Cancer. 1992;70:1493-1497.
4. Henson DE, Albores-Saavedra J, Corle D. Carcinoma of the extrahepatic bile ducts. Histologic types, stage of disease, grade, and survival rates. Cancer. 1992;70:1498-1501.
5. Carriaga MT, Henson DE. Liver, gallbladder, extrahepatic bile ducts, and pancreas. Cancer. 1995;75:171-190.
6. Shirasaka T, Nakano K, Fukushima M, et al. Antitumor activity of 1M-tegaful-0.4 M 5-chloro-2,4-dihydroxypyridine-1M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res. 1996;56:2602-2606.
7. Au JL, Sadee W. Activation of Ftorafur [R,S-1-(tetrahydro-2-furanyl)-5- fluorouracil] to 5-fluorouracil and gamma-butyrolactone. Cancer Res. 1980;40:2814-2819.
8. Tatsumi K, Fukushima M, Shirasaka T, et al. Inhibitory effects of pyrimidine, barbituric acid and 1 pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. Jpn J Cancer Res. 1987;78:748-755.
9. Shirasaka T, Shimamoto Y, Fukushima M. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res. 1993;53:4004-4009.
10. Sakata Y, Ohtsu A, Horikoshi N, et al. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer. 1998;34:1715-1720.
11. Ohtsu A, Baba H, Sakata Y, et al. Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma. Br J Cancer. 2000;83(2):141-145.
12. Sano N, Saeki T, Takashima S, et al. Late Phase II study of S-1 in Patients with advanced and/or recurrent breast cancer. Proc Am Soc Clin Oncol. 2001;20:404.
13. Ueno H, Okusaka T, Ikeda M, et al. Phase II study of S-1 in patients with biliary tract cancer. Br J Cancer. 2004;91:1769-1774.
14. Hayashi K, Imaizumi T, Uchida K, et al. High response rate in patients with pancreatic cancer using the novel oral flioropyrimidine S-1. Oncol Rep. 2002;9:1355-1361.
15. Polyzos A, Nikou G, Giannopoulos A, et al. Chemotherapy of biliary tract cancer with mitomycin C and 5-FU biologically modulated by folic acid. Ann Oncol. 1996;7:644-645.
16. Ducreux M, Rouier P, Fandi A, et al. Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin. Ann Oncol. 1998;9:653-656.
17. Taieb J, Mitry E, Bioge V, at el. Optimization of 5-fluorouracil/ cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin in patients with biliary tract carcinoma. Ann Oncol. 2002;13:1192-1196.
18. Mezger J, Sauerbruch T, Ko Y, et al. Phase II study of gemcitabine in gallbladder and biliary tract carcinomas. Oncologie. 1998;21:232-234.
19. Tsavaris N, Kosmas C, Gouveris P et al. Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer. Invest New Drugs. 2004;22:193-198.
20. Hejna M, Pruckmayer M, Raderer M. The role of chemotherapy and radiation in the management of biliary cancer: a review of the literature. Eur J Cancer. 1998;34:977-986.
21. Kitamura Y, Hayashi K, Yamada T, et al. A split protocol of cisplatinum (CDDP) infusion in outpatients. J Appl Res. 2004;4:215-221.